Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
İmegeria is a gadolinium-based contrast agent (GBCA) containing gadoteric acid (as gadoterate meglumine), developed and marketed by Biem. It is a macrocyclic, ionic paramagnetic molecule used to enhance image quality in magnetic resonance imaging (MRI). By shortening the T1 and T2 relaxation times of water protons in the body, gadoteric acid increases the signal intensity of tissues where it distributes, facilitating the visualization of lesions, tumors, and vascular structures. Due to its macrocyclic structure, it exhibits high thermodynamic stability and low kinetic dissociation, reducing the risk of gadolinium release. İmegeria is approved for use in cranial, spinal, and whole-body MRI in both adult and pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gadoteric acid.